David Brown
Psychiatry · Austin, TXNPI 1518086743
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,412 of the $42,043 with a category attached, or 72.3%. 17 manufacturers reported payments, led by Alkermes, Inc. at 38.9% of the total. Reporting peaked in 2022 at $18,807 and has fallen 55.1% since, to $8,450 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 272 payments — averaging $154.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$16K
- Biogen$14K
- E.r. Squibb & Sons, L.L.C.$8K
- Otsuka America Pharmaceutical, Inc.$776
- Teva Pharmaceuticals USA, Inc.$685
- Sunovion Pharmaceuticals Inc.$509
- plus $2K from 11 others
Across 1,132 payments — averaging $13,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4.2M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.3M
- Teva Pharmaceuticals USA, Inc.$2.8M
- AbbVie$1.9M
- Vanda Pharmaceuticals Inc.$875K
- Hoffmann-la Roche Limited$774K
- plus $1.9M from 15 others
What the payments were for
- Consulting fees$4,67511%
- Speaking & faculty fees$30,41272%
- Travel & lodging$1,5974%
- Food & beverage$5,35813%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 46 | $16,375 |
| Biogen | 3 | $13,792 |
| E.r. Squibb & Sons, L.L.C. | 16 | $8,115 |
| Otsuka America Pharmaceutical, Inc. | 46 | $776 |
| Teva Pharmaceuticals USA, Inc. | 32 | $685 |
| Sunovion Pharmaceuticals Inc. | 45 | $509 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $452 |
| Vanda Pharmaceuticals Inc. | 19 | $358 |
| Johnson & Johnson | 9 | $186 |
| Neurocrine Biosciences, Inc. | 6 | $156 |
| Indivior Inc. | 7 | $152 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $135 |
| Boehringer Ingelheim | 2 | $122 |
| AbbVie(2 entities) | 5 | $88 |
| Lundbeck LLC | 5 | $71 |
| Merck | 5 | $42 |
| Bioxcel Therapeutics, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,043 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 14 | $12,285 |
| Dextroamphetamine Sulfate | 11 | $3,391 |
| Olanzapine | 24 | $1,044 |
| Pregabalin | 25 | $517 |
| Aripiprazole | 12 | $337 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $336 |
| Gabapentin | 15 | $292 |
| Mirtazapine | 14 | $250 |
| Clonazepam | 13 | $233 |
| Clozapine OdtClozapine | 16 | $229 |
| Alprazolam | 16 | $132 |
| Fluoxetine Hcl | 25 | $109 |
| Lorazepam | 20 | $68 |
| Cyclobenzaprine Hcl | 12 | $12 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $135 | $12,28514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Charles NemeroffAustin$429K
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.